Company intelligence / Profile preview
Duality Biotherapeutics
Suzhou, Jiangsu, Chinaen.dualitybiologics.com ↗
- Ownership
- Public · 9606.HK
- Development stage
- Phase 3
01
Overview
Duality Biotherapeutics has advanced several antibody-drug conjugates into global clinical trials across more than a dozen countries with over seven candidates in the clinic. Lead asset DB‑1303 is in Phase 3 for HER2-expressing cancers with plans for accelerated approval filings as early as late 2025. Other advanced programs target B7-H3 and TROP2 with Fast Track or Breakthrough Therapy Designations from the FDA for certain indications. The company’s first-in-class autoimmune ADC program is entering human studies for lupus erythematosus.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Antibody-drug conjugateBispecific monoclonal antibodyMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
BioNTech – exclusive license/collaboration on multiple lead assets including global rights to develop/manufacture/commercialize select ADCs outside Greater China region.BeiGene – licensed rights to a candidate targeting B7-H4.Avenzo Therapeutics – exclusive global license agreement for EGFR/HER₃ bispecific ADC program.Adcendo – partnership details not fully specified but part of >$4 billion deal value across partnerships.
04
Financials
- Market cap
- $1.2B
- Total revenue
- $270.4M
- Enterprise value
- $840.8M
Beyond the preview
Go deeper on Duality Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duality Biotherapeutics.